|

VMD-928 Tablet and Pembrolizumab (200 mg) Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Combination therapy

Pipeline

Phase 1/2: 1

Top Sponsors

  • VM Oncology, LLC1

Indications

  • Head and Neck Cancers Trachea1
  • Head and Neck Cancers Oropharynx1
  • Head and Neck Cancers Oral Cavity1
  • Head and Neck Cancers Nasopharynx1
  • Head and Neck Cancers Lip1

Santa Rosa, California1 trial

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Providence Medical Foundation (site 209)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.